Infliximab (IFX)-Biosimilar Induced Drug-Induced Liver Injury (DILI): A Case Report

Infliximab (IFX) is a chimeric human-murine monoclonal antibody that prevents tumor necrosis factor alpha (TNF-α) activation by binding to both soluble and transmembrane forms of TNF-α. Antagonists of TNF (anti-TNF agents) can cause drug-induced liver injury (DILI). We present a non-anti-TNF naïve p...

Descripción completa

Detalles Bibliográficos
Autores principales: Zachou, Maria, Pikramenos, Konstantinos, Panoutsakou, Maria, Lalla, Efthimia, Androutsakos, Theodoros
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Internal Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9839355/
https://www.ncbi.nlm.nih.gov/pubmed/36654618
http://dx.doi.org/10.7759/cureus.32525
Descripción
Sumario:Infliximab (IFX) is a chimeric human-murine monoclonal antibody that prevents tumor necrosis factor alpha (TNF-α) activation by binding to both soluble and transmembrane forms of TNF-α. Antagonists of TNF (anti-TNF agents) can cause drug-induced liver injury (DILI). We present a non-anti-TNF naïve patient suffering from severe Crohn’s disease who developed DILI with a hepatocellular pattern, without jaundice, after two infusions of an IFX biosimilar.

Ejemplares similares